ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.

Zhejiang Huahai Pharmaceutical Co., Ltd.

600521

CNE000001DL5

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
16.05 ^CNY	+1.33%		+6.72%	+9.41%

Apr. 24	Huahai Pharmaceutical Gets Approval to Market Busulfan Injection	MT
Apr. 19	Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.	CI

Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 6, 2021.

October 07, 2021

From August 5, 2021 to September 30, 2021, the company has repurchased 3,041,915 shares, representing 0.2% for CNY 52.05 million. With this, the company has completed the repurchase of 3,041,915 shares, representing 0.2% for CNY 52.05 million under the buyback announced on August 6, 2021.

Latest news about Zhejiang Huahai Pharmaceutical Co., Ltd.

Huahai Pharmaceutical Gets Approval to Market Busulfan Injection	Apr. 23	MT
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.	Apr. 18	CI
Zhejiang Huahai Pharmaceutical Gets Chinese Registration Nod for Torsemide Tablets	Apr. 17	MT
Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 14, 2023 has closed with 7,023,600 shares, representing 0.48% for CNY 99.99 million.	Apr. 16	CI
Zhejiang Huahai Pharmaceutical Forecasts Up to 65% Rise in Q1 Profit	Apr. 16	MT
Shyndec Pharmaceutical's Unit Gets Nod to Register Empagliflozin Tablets	Apr. 16	MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.	Apr. 01	CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.	Jan. 02	CI
Zhejiang Huahai Pharmaceutical Gets US FDA's Nod for Pemetrexed Disodium for Injection	Dec. 18	MT
Correction: Huahai Pharmaceutical Gets Nod to Amend Specifications for Irbesartan Tablets	Dec. 11	MT
Huahai Pharmaceutical Gets Nod to Amend Spefication for Irbesartan Tablets	Dec. 11	MT
Zhejiang Huahai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	Nov. 13	CI
Huahai Pharma Selling 1.4 Billion Yuan Shares For Capacity Expansion	Nov. 10	MT
Huahai Pharma to Repurchase Up to 100 Million Yuan Shares	Nov. 06	MT
Huahai Pharma Unit Gets FDA Nod to Trial Cancer Drug	Nov. 06	MT
Zhejiang Huahai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Nov. 05	CI
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Huahai Pharma Registers Drug for Prostate Treatment	23-10-19	MT
Ningbo Menovo Pharma Registers Blood Pressure Drug	23-09-06	MT
Huahai Pharmaceutical Gets US FDA's Nod for Dicyclomine Hydrochloride Capsules	23-09-04	MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Zhejiang Huahai Pharmaceutical's Units Gain Nod to Trial Cancer Drug Combination	23-07-12	MT
Shanghai Ddsome Laboratories Co., Ltd announced that it has received funding from Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang Starry Pharmaceutical Co.,Ltd.	23-07-06	CI
Zhejiang Huahai Pharma Registers Anticoagulant Drug	23-05-09	MT

Chart Zhejiang Huahai Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Huahai Pharmaceutical Co., Ltd.

More charts

Company Profile

ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The Company also provides related technical support services. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Huahai Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.05 CNY

Average target price

16.37 CNY

Spread / Average Target

+1.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.	+9.41%	3.22B
ELI LILLY AND COMPANY	+26.04%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.65%	354B
MERCK & CO., INC.	+20.79%	331B
ABBVIE INC.	+2.66%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-5.90%	144B

Other Pharmaceuticals

Zhejiang Huahai Pharmaceutical Co., Ltd.

Equities

600521

CNE000001DL5

Pharmaceuticals

Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 6, 2021.

EPS Revisions